Amarin Corp Plcuk (AMRN) Non-Current Deffered Revenue (2015 - 2024)
Amarin Corp Plc\Uk (AMRN) posted quarterly Non-Current Deffered Revenue of $2.1 million for Q1 2024, down 83.4% year-over-year from $12.7 million in Q2 2023, and down 15.98% quarter-over-quarter from $2.5 million in Q4 2023.
Amarin Corp Plcuk (AMRN) Non-Current Deffered Revenue (2015 - 2024) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Non-Current Deffered Revenue for 10 consecutive years, with $2.1 million the latest figure, recorded in Q1 2024.
- In Q1 2024, Non-Current Deffered Revenue fell 83.4% year-over-year to $2.1 million; the TTM figure through Mar 2024 stood at $2.1 million (down 83.4% YoY), while the FY2023 annual figure was $2.5 million, down 80.92% from the prior year.
- Non-Current Deffered Revenue declined to $2.1 million in Q1 2024 per AMRN's latest filing, from $2.5 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $17.5 million in Q1 2020 and bottomed at $2.1 million in Q1 2024.
- Historically, Non-Current Deffered Revenue has averaged $11.6 million across 5 years, with a median of $13.8 million in 2022.
- Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue rose 9.75% — and 2024, when it plunged 83.4%.
- Amarin Corp Plc\Uk's Non-Current Deffered Revenue stood at $15.7 million in 2020, then declined by 10.48% to $14.1 million in 2021, then fell by 6.49% to $13.1 million in 2022, then slumped by 80.92% to $2.5 million in 2023, then fell by 15.98% to $2.1 million in 2024.
- Business Quant data shows AMRN's Non-Current Deffered Revenue at $2.1 million in Q1 2024, $2.5 million in Q4 2023, and $2.9 million in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 2.11 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Sep 30, 2023 | 2.95 Mn |
| Jun 30, 2023 | 3.33 Mn |
| Mar 31, 2023 | 12.70 Mn |
| Dec 31, 2022 | 13.15 Mn |
| Sep 30, 2022 | 13.50 Mn |
| Jun 30, 2022 | 13.81 Mn |
| Mar 31, 2022 | 14.14 Mn |
| Dec 31, 2021 | 14.06 Mn |
| Sep 30, 2021 | 14.49 Mn |
| Jun 30, 2021 | 14.83 Mn |
| Mar 31, 2021 | 15.20 Mn |
| Dec 31, 2020 | 15.71 Mn |
| Sep 30, 2020 | 13.20 Mn |
| Jun 30, 2020 | 14.51 Mn |
| Mar 31, 2020 | 17.52 Mn |
| Dec 31, 2019 | 18.50 Mn |
| Sep 30, 2019 | 17.62 Mn |
| Jun 30, 2019 | 17.78 Mn |